Neurocrine Biosciences
NBIX
#1633
Rank
C$13.89 B
Marketcap
$140.48
Share price
1.28%
Change (1 day)
-23.43%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $2.63

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $2.72. In 2022 the company made an earnings per share (EPS) of $2.23 an increase over its 2021 EPS that were of $1.32.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$2.6318.06%
2022$2.2369.47%
2021$1.32-78.21%
2020$6.04990%
2019$0.5581.82%
2018$0.30-113.5%
2017-$2.260.62%
2016-$2.2457.28%
2015-$1.4325.61%
2014-$1.1418.84%
2013-$0.96-1085.71%
2012$0.09700-89.71%
2011$0.94-500%
2010-$0.24-86.92%
2009-$1.80-43.48%
2008-$3.19-57.8%
2007-$7.5592.58%
2006-$3.92371.67%
2005-$0.83-52.76%
2004-$1.7636.56%
2003-$1.29-70%
2002-$4.30118.31%
2001-$1.978.4%
2000-$1.8248.86%
1999-$1.22-20%
1998-$1.52-479.31%
1997$0.40

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$2.90 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.76-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.10-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.52 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.10 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.58-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.65-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.20-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA